

- pediatrics. 2018;73(3):139-145.
126. Ravindran A, Go RS, Fervenza FC, et al. Thrombotic microangiopathy associated with monoclonal gammopathy. *Kidney Int.* 2017;91(3):691-698.
 127. Rigother C, Delmas Y, Roumenina LT, et al. Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgA antibody. *Am J Kidney Dis.* 2015;66(2):331-336.
 128. Cheungpasitporn W, Leung N, Sethi S, et al. Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy. *Clin Nephrol.* 2015;83(6):363-369.
 129. Ciocchini M, Musso CG. Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy? *Int Urol Nephrol.* 2018;50(7):1365-1366.
 130. Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. *Front Immunol.* 2021;12:780107. doi: 10.3389/fimmu.2021.780107.
 131. Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. *Am J Hematol.* 2017;92(8):814-829.
 132. Král Z, Krejčí M, Pour L, et al. POEMS syndrom – vzácné onemocnění asociované s monoklonální gamapatií a polyneuropatií: diagnostika a terapie. *Transfúze a hematologie dnes.* 2021;27(3):226-231.
 133. Li J, Huang Z, Duan MH, et al. Characterization of immunoglobulin A light chain variable region (IGLV) gene and its relationship with clinical features in patients with POEMS syndrome. *Ann Hematol.* 2012;91(8):1251-1255.
 134. Leebeek FWG. New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome. *Hemisphere.* 2021;5(6):e586. doi: 10.1097/HS9.0000000000000586.
 135. Dulíček P, Maisnar V. Možné klinické projevy přítomnosti M-Ig. Změny hemostázy vlivem přítomnosti monoklonálního imunoglobulinu. *Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu.* Praha: Nucleus HK; 2012. p. 90-92.
 136. Špička I, Cieslar P, Hrkál Z, et al. Vliv paraproteinu na antitrombotické mechanismy - další typ interference paraproteinu s hemostázou: Časopis lékařů českých. 1996;135(4):126.
 137. Strobhach SROV. Expression of Gplb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. *Br J Haematol.* 1993;84(3):471-475.
 138. Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. *Br J Haematol.* 2000;110(2):454-460.
 139. Santoro M, Romano A, Mancuso S, et al. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. *Panminerva Med.* 2021;63(1):1-6. doi: 10.23736/S0031-0808.20.04133-6.
 140. Swan D, Rocci A, Bradbury C, et al. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. *Br J Haematol.* 2018;183(4):538-556. doi: 10.1111/bjh.15684.
 141. Szalat R, Monsel G, Le W, et al. The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: association with IgA isotype and inflammatory profile. *J Am Acad Dermatol.* 2015;73(5):809-820.
 142. Filosa A, Filosa G. Neutrophilic dermatoses: a broad spectrum of disease. *G Ital Dermatol Venereol.* 2018;153(2):265-272. doi: 10.23736/S0392-0488.18.05841.
 143. Young PA, Bae GH, Konia TH. Subcorneal pustular dermatosis associated with IgG monoclonal gammopathy of undetermined significance. *Dermatol Online J.* 2021;27(4):13030/qt71k801d3.
 144. Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. *J Am Acad Dermatol.* 2013;69(1):66-72.
 145. Wigley F, Nazarian RM. Case 8-2015: a man with multiple myeloma, skin tightness, arthralgias, and edema. *N Engl J Med.* 2015;372(11):1056-1067.
 146. Urbanček S. Skleredém a skleromyxedém. *Česká dermatovenerologie.* 2018;8(2):87-88.
 147. Štítná M, Rasochová E. Klinický případ: Diseminované voskové papulky a facies leontina. *Československá dermatologie.* 2012;87(2):57-59.
 148. Adam Z, Szturcz P, Krejčí M, et al. Monoklonální imunoglobulin a kožní nemoci ze skupiny mucinóz – scleredema adultorum Buschke a scleromyxedema: popis 4 případů a přehled léčebných možností. *Vnitř. lék.* 2015;61(12):1072-1087.
 149. Adam Z, Szturcz P, Pour L, et al. Kožní projevy monoklonálních gamapatií – zkušenosti jednoho pracoviště. *Česká dermatovenerologie.* 2011;1(2):30-37.
 150. Král Z, Krejčí M, Pour L, et al. Vzácné kožní změny asociované s monoklonální gamapatií: skleredém, skleromyxedém a IgA pemfigus – popis pěti případů a přehled léčebných možností. *Transfúze a hematologie dnes.* 2020;26(3):226-235.
 151. Szturcz P, Adam Z, Vašků V, et al. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. *Leukemia & lymphoma.* 2013;54(6):1324-1326.
 152. Keragala BSDP, Herath HMMTB, Janapriya GHDC, et al. Scleredema associated with immunoglobulin A-k smoldering myeloma: a case report and review of the literature. *J Med Case Rep.* 2019;13(1):145. doi: 10.1186/s13256-019-2072-1.
 153. O'Malley JT, D'Agati VD, Sherman WH, et al. Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers. *JAMA Dermatol.* 2014;150(11):1192-1196.
 154. Jachiet M, Harel S, Saussine A, et al. Étude des Maladies Systémiques en Dermatologie; Groupe d'Étude des Dermatoses Associées à une Immunoglobuline Monoclonale. *Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature.* *J Am Acad Dermatol.* 2018;79(5):945-947. doi: 10.1016/j.jaad.2018.03.039.
 155. Rowczenio DM, Pathak S, Arostegui I, et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. *Blood.* 2018;131(9):974-981.
 156. Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease). *J Allergy Clin Immunol.* 2017;140(3):663-670.
 157. Ounci-Essad, Bouchlarhem A, Lamzouri O, et al. Consider systemic capillary leak syndrome in monoclonal gammopathy with shock. *Ann Med Surg (Lond).* 2021;72:103013. doi: 10.1016/j.jamsu.2021.103013.
 158. Shin JI, Lee JS. Beneficial effect of intravenous immunoglobulins on systemic capillary leak syndrome in patients with monoclonal gammopathy. *Crit Care Med.* 2009;37(2):795-798. doi: 10.1097/CCM.0b013e3181959c3d.
 159. Mullane R, Langewisch E, Florescu M, et al. Chronic systemic capillary leak syndrome treatment with intravenous immune globulin: Case report and review of the literature. *Clin Nephrol.* 2019;91(1):59-63. doi: 10.5414/CN109467.
 160. Doubek M, Brychtová Y, Tomiška M, et al. Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. *Acta haematologica.* 2005;113(2):150-151.
 161. Sobotková M, Segethová J. Získaný angioedém s deficitem C1 inhibitoru u pacientky s B-lymfomem nízké malignity a efekt léčby základního onemocnění na projevy angioedému. *Transfúze a hematologie dnes.* 2017;23(3):145-150.
 162. Šedivá D, Stříž I. Získaný angioedém v důsledku deficitu C1-inhibitoru. 2000;2(4):272-275.
 163. Sobotková M, Zachová R, Hák P, et al. Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients. *International archives of allergy and immunology.* 2021;182(7):642-649.
 164. Sykes DB, Schroyens W, O'Connell C. The TEMPI syndrome: a novel multisystem disease. *N Engl J Med.* 2011;365(5):475-477.
 165. Zhang X, Fang M. TEMPI syndrome: Erythrocytosis in plasma cell dyscrasia. *Clin Lymphoma Myeloma Leuk.* 2018;18:724-730.
 166. Kwok M, Korde N, Landgren O. Bortezomib to treat the TEMPI syndrome. *N Engl J Med.* 2012;366(19):1843-1845.
 167. Adam Z, Kisořová J, Pour L, et al. Myopatie při Waldenströmově makroglobulinemii. Popis případů a přehled autoimunitních projevů monoklonálních imunoglobulinů typu IgM. *Vnitř. lék.* 2015;61(9):821-828.
 168. Uruha A, Benveniste O. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. *Curr Opin Neurol.* 2017;30(5):457-463.
 169. Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. *Orphanet J Rare Dis.* 2017;12(1):86-87. doi: 10.1186/s13023-017-0640-2. PMID: 28490364.
 170. Forgáč M, Uher T, Zámečník J. Nemaligní Myopatie asociovaná s monoklonální gamapatií – kazuistika. *Česká a slovenská neurologie a neurochirurgie.* 2014;77(2):247-250.
 171. Král Z, Krejčí M, Pour L, et al. Bolesti svalů jako vzácný autoimunitní projev při monoklonální IgM gamapatií – popis případů a přehled autoimunitních projevů monoklonálních imunoglobulinů. *Transfúze a hematologie dnes.* 2021;27(1):57-61.
 172. Musilová L, Kryšťuková O. Monoklonální gamapatie u systémových onemocnění pojiva. *Rheumatologia.* 2002;16(1):31-36.
 173. Lichtman MA, Balderman SR. Unusual manifestations of essential monoclonal gammopathy: II. Simulation of the insulin autoimmune syndrome. *Rambam Maimonides Med J.* 2015;6(3):e0027.
 174. Shah S, Espana EM, Margo CE. Ocular manifestations of monoclonal copper-binding immunoglobulin. *Surv Ophthalmol.* 2014;59(1):115-123.
 175. Hradská K, Jelínek T, Ďuraš J, et al. Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma. Case report and review of literature. *Transfúze a hematologie dnes.* 2020;26(9):90-95.
 176. Arnulf B, Bengoufa D, Sarfati E, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. *Arch Intern Med.* 2002;162(4):464-467.
 177. Syler LB, Gooden C, Riddle N. Plasma Cell Myeloma Within a Renal Cell Carcinoma, an Intimate Histologic Relationship: A Case Report and Literature Review. *Cureus.* 2021;13(1):e12898.
 178. Xu G, Yang M, Huang J, Jin J. Coexistence of multiple myeloma and clear cell renal cell carcinoma: a case report and review of literature. *Int J Clin Exp Pathol.* 2015;8(6):7627-7630.
 179. Bridoux F, Javaugue V, Bender S, et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. *Kidney Int.* 2017;91(2):423-434.
 180. Atzori L, Ferrel C, Rongioletti F. New insights on scleromyxedema. *J Scleroderma Relat Disord.* 2019;4(2):118-126. doi: 10.1177/2397198318824929.
 181. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nat Rev Nephrol.* 2019;15(1):45-59. doi: 10.1038/s41581-018-0077-4.
 182. Jain A, Haynes R, Kothari J, et al. Pathophysiology and management of monoclonal gammopathy of renal significance. *Blood Adv.* 2019;3(15):2409-2423. doi: 10.1182/bloodadvances.2019031914. PMID: 31409583.
 183. de Chambrun P, Gousseff M, Mauhin W, et al. EurEClark Study Group. Intravenous immunoglobulins improve survival in monoclonal gammopathy-associated systemic capillary-leak syndrome. *Am J Med.* 2017;130(10):1219.e19-1219.e27.
 184. Moreno DF, Rosiñol L, Cibeira MT, et al. Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. *Cancers (Basel).* 2021;13(20):5131. doi: 10.3390/cancers13205131. PMID: 34680279.